secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2021-07-29T23:59:59+00:00
Accession:  0000875320-21-000024
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vertex Q2 product revenues $1.79B (+18% YoY); raises FY 2021 guidance to $7.2-7.4B
--------------------------------------------------------------------------------

- Product revenues $1.793B, up 18% YoY; TRIKAFTA/KAFTRIO $1.256B led growth.
- GAAP net income $67M ($0.26 diluted EPS); non-GAAP net income $811M ($3.11 EPS).
- Raised full-year 2021 product revenue guidance to $7.2-7.4B from $6.7-6.9B.
- Recorded $900M payment to CRISPR in Q2 as R&D expense, impacting GAAP results.
- CTX001 dosed >45 patients; target enrollment in Phase 3 studies expected Q3 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532021000024/0000875320-21-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532021000024/vrtx-20210729.htm
  HTML page:      https://secwatch.observer/filing/0000875320-21-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer